MSBase

MSBase
Name	MSBase
Formation	2004
Type	International clinical registry and research collaboration
Headquarters	Melbourne, Australia
Region served	Global

MSBase

MSBase is an international, collaborative clinical registry and research network focused on multiple sclerosis that aggregates longitudinal patient data to support observational studies, health services research, and practice-improvement initiatives. The platform links specialist clinics, academic centres, and hospital systems to enable large-scale analyses that inform clinical care, guideline development, and regulatory assessments. MSBase emphasizes real-world evidence through routine clinical data curation, harmonization, and analytic pipelines across participating sites in diverse health systems.

Overview

MSBase functions as a multicentre registry and research consortium integrating data from neurologists, academic institutions, and specialty clinics across regions including Australia, Europe, North America, Asia, and South America. The network supports studies on disease-modifying therapies, disease progression, health outcomes, and pharmacovigilance involving stakeholders such as the World Health Organization, national health agencies, academic hospitals like Royal Melbourne Hospital, and specialty centres like the Mayo Clinic. MSBase combines clinical phenotypes, imaging reports, and treatment exposure data to address questions relevant to organizations such as the European Medicines Agency and the U.S. Food and Drug Administration.

History and Development

MSBase was initiated in the early 2000s by clinicians and researchers affiliated with institutions including University of Melbourne and developed collaborative ties with international groups such as the European Academy of Neurology and the American Academy of Neurology. Major milestones include expansion from regional pilot registries to a federated international network, adoption of standardized case-report forms influenced by initiatives like the International Advisory Committee on Clinical Trials in Multiple Sclerosis, and integration with electronic health record systems used by hospitals such as Royal Prince Alfred Hospital. The registry evolved through partnerships with academic research centres at universities like Monash University and University College London as well as with specialty research networks including the Consortium of Multiple Sclerosis Centers.

Governance and Funding

MSBase governance includes an international steering committee composed of neurologists and centre leads from institutions such as Charité – Universitätsmedizin Berlin, Oxford University Hospitals, and Toronto General Hospital. Funding sources have combined philanthropic grants, academic research funding from bodies like the National Health and Medical Research Council (Australia), investigator-initiated grants from organizations such as the European Commission, and collaborative funding with industry partners including pharmaceutical companies involved in multiple sclerosis therapeutics. Oversight mechanisms incorporate ethics committees at participating hospitals and guidance from professional societies including the International Federation of Clinical Chemistry and Laboratory Medicine and specialty groups like the International Multiple Sclerosis Genetics Consortium.

Data Collection and Registry Structure

MSBase collects longitudinal clinical data using standardized electronic case-report forms capturing demographics, disease course descriptors used by the Expanded Disability Status Scale, relapse history, treatment exposures including disease-modifying therapies approved by agencies like the European Medicines Agency and U.S. Food and Drug Administration, and imaging summaries from scanners at centres such as Johns Hopkins Hospital. The registry employs a federated architecture allowing local data custodians at hospitals like St. Vincent’s Hospital, Sydney to retain control while enabling de-identified aggregated analyses. Data harmonization leverages common data models influenced by initiatives such as the Observational Medical Outcomes Partnership and quality-control protocols developed in collaboration with research units at Harvard Medical School and Karolinska Institutet.

Research Contributions and Publications

MSBase has produced influential observational studies on comparative effectiveness and safety of therapies produced by pharmaceutical companies including studies relevant to agents licensed following approvals by the European Medicines Agency and the U.S. Food and Drug Administration. Publications from the network have appeared in journals linked to institutions like The Lancet, New England Journal of Medicine, and specialty journals associated with the American Academy of Neurology. Collaborative analyses have addressed prognostic modelling, risk stratification, and treatment sequencing with contributions from research groups at Massachusetts General Hospital, University of Oxford, and Charité – Universitätsmedizin Berlin. MSBase investigators have presented findings at conferences organized by bodies such as the European Committee for Treatment and Research in Multiple Sclerosis and the European Academy of Neurology.

Clinical Impact and Practice Guidelines

Evidence generated through MSBase has informed clinical practice via contributions to guideline panels convened by organizations such as the European Academy of Neurology and the American Academy of Neurology. Registry-derived analyses have influenced recommendations on treatment initiation, escalation strategies, and monitoring practices used in centres like Royal Melbourne Hospital and Mayo Clinic. Findings on real-world safety and effectiveness have been cited in health technology assessments by agencies including the National Institute for Health and Care Excellence and have been used by hospital formularies in systems such as NHS England to refine therapeutic pathways.

Privacy, Ethics, and Data Security

MSBase operates under ethics approvals from institutional review boards at participating centres including those at University of Melbourne and Karolinska Institutet and adheres to data protection frameworks comparable to regulations such as the General Data Protection Regulation enacted by the European Union. The registry uses de-identification, secure transfer protocols, and local data governance consistent with standards promoted by organizations like the International Medical Informatics Association and audit practices from institutions such as Johns Hopkins University. Ethical oversight addresses secondary use of data, consent models, and linkage to administrative datasets managed by national agencies including Australian Institute of Health and Welfare.

Category:Medical registries